This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strome, S. E. Articles by Chen, L. Search for Related Content PubMed PubMed Citation Articles by Strome, S. E. Articles by Chen, L.

Strategies for Antigen Loading of Dendritic Cells to Enhance the Antitumor Immune Response¹

Departments of Otolaryngology [S. E. S., T. L. W., J. L. K.], Immunology [S. V., R. W., K. T., D. F., A. C., J. L., P. W., L. C.], Molecular Medicine Program [R. V.], and Transfusion Medicine [D. P., D. G.], Mayo Clinic, Rochester, Minnesota 55905

Dendritic cells (DCs) primed with tumor antigens can effectively mediatethe regression of a variety of established solid malignancies in both murine and human models. Despite such clinical efficacy, the optimal means of DC priming is unknown. The goal of this study was to compare three methods of tumor preparation: irradiation, boiling, or freeze thaw lysis for DC priming. Mouse bone marrow-derived DCs were loaded with defined ratios of E.G7 tumor cells expressing a model tumor antigen, OVA. Sensitized DCs were used for stimulation of OVA-specific CTLs derived from OT-1 T-cell receptor transgenic mice. IFN- release, determined by ELISA at 24 and 48 h, was used to assess the expression of antigens by DCs. DCs loaded with irradiated tumors were effective stimulators for OT-1 CTLs, whereas DCs stimulated with freeze-thawed or boiled tumors did not stimulate IFN- production. Freeze-thaw lysis appeared to inhibit CTL activity in vitro and in two of three cases, this effect was not overcome by the addition of OVA. The ability to load irradiated tumor cells was reproduced in two analogous human melanoma models using melanoma cell lines expressing gp100 and CTL clones specific for a gp100 melanoma antigen. Consistent with the in vitro data, only DC/irradiated tumor vaccines were effective in preventing or delaying outgrowth of E.G7 and a poorly immunogenic murine squamous cell carcinoma (SCCVII), on local tumor challenge. These data demonstrate that the method of tumor cell preparation clearly influences the ability of DCs to present antigen to T cells. Correlation of in vitro data with the generation of protective immunity in vivo suggests the utility of irradiated tumor-primed DCs as a means to generate protective immunity in patients with solid malignancies.

This article has been cited by other articles:

				R. L. VanOosten and T. S. Griffith Activation of Tumor-Specific CD8+ T Cells after Intratumoral Ad5-TRAIL/CpG Oligodeoxynucleotide Combination Therapy Cancer Res., December 15, 2007; 67(24): 11980 - 11990. [Abstract] [Full Text] [PDF]

				S. Darmanin, J. Chen, S. Zhao, H. Cui, R. Shirkoohi, N. Kubo, Y. Kuge, N. Tamaki, K. Nakagawa, J.-i. Hamada, et al. All-trans Retinoic Acid Enhances Murine Dendritic Cell Migration to Draining Lymph Nodes via the Balance of Matrix Metalloproteinases and Their Inhibitors J. Immunol., October 1, 2007; 179(7): 4616 - 4625. [Abstract] [Full Text] [PDF]

				J. S. Wolf, G. Li, A. Varadhachary, K. Petrak, M. Schneyer, D. Li, J. Ongkasuwan, X. Zhang, R. J. Taylor, S. E. Strome, et al. Oral Lactoferrin Results in T Cell-Dependent Tumor Inhibition of Head and Neck Squamous Cell Carcinoma In vivo Clin. Cancer Res., March 1, 2007; 13(5): 1601 - 1610. [Abstract] [Full Text] [PDF]

				S. Shibata, S. Okano, Y. Yonemitsu, M. Onimaru, S. Sata, H. Nagata-Takeshita, M. Inoue, T. Zhu, M. Hasegawa, Y. Moroi, et al. Induction of Efficient Antitumor Immunity Using Dendritic Cells Activated by Recombinant Sendai Virus and Its Modulation by Exogenous IFN-beta Gene J. Immunol., September 15, 2006; 177(6): 3564 - 3576. [Abstract] [Full Text] [PDF]

				A. Harui, M. D. Roth, D. Vira, M. Sanghvi, H. Mizuguchi, and S. K. Basak Adenoviral-encoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of {alpha}v{beta}3 integrins J. Leukoc. Biol., June 1, 2006; 79(6): 1271 - 1278. [Abstract] [Full Text] [PDF]

				N. Casares, M. O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux, N. Chaput, E. Schmitt, A. Hamai, S. Hervas-Stubbs, M. Obeid, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J. Exp. Med., December 19, 2005; 202(12): 1691 - 1701. [Abstract] [Full Text] [PDF]

				G. Driessens, M. Hamdane, V. Cool, T. Velu, and C. Bruyns Highly Successful Therapeutic Vaccinations Combining Dendritic Cells and Tumor Cells Secreting Granulocyte Macrophage Colony-stimulating Factor Cancer Res., November 15, 2004; 64(22): 8435 - 8442. [Abstract] [Full Text] [PDF]

				E. Schmitt, A. Parcellier, F. Ghiringhelli, N. Casares, S. Gurbuxani, N. Droin, A. Hamai, M. Pequignot, A. Hammann, M. Moutet, et al. Increased Immunogenicity of Colon Cancer Cells by Selective Depletion of Cytochrome c Cancer Res., April 15, 2004; 64(8): 2705 - 2711. [Abstract] [Full Text] [PDF]

				S. Teitz-Tennenbaum, Q. Li, S. Rynkiewicz, F. Ito, M. A. Davis, C. J. Mcginn, and A. E. Chang Radiotherapy Potentiates the Therapeutic Efficacy of Intratumoral Dendritic Cell Administration Cancer Res., December 1, 2003; 63(23): 8466 - 8475. [Abstract] [Full Text] [PDF]

				R. S. Goldszmid, J. Idoyaga, A. I. Bravo, R. Steinman, J. Mordoh, and R. Wainstok Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma J. Immunol., December 1, 2003; 171(11): 5940 - 5947. [Abstract] [Full Text] [PDF]

				S. E. Strome, H. Dong, H. Tamura, S. G. Voss, D. B. Flies, K. Tamada, D. Salomao, J. Cheville, F. Hirano, W. Lin, et al. B7-H1 Blockade Augments Adoptive T-Cell Immunotherapy for Squamous Cell Carcinoma Cancer Res., October 1, 2003; 63(19): 6501 - 6505. [Abstract] [Full Text] [PDF]

				L. Rivoltini, C. Castelli, M. Carrabba, V. Mazzaferro, L. Pilla, V. Huber, J. Coppa, G. Gallino, C. Scheibenbogen, P. Squarcina, et al. Human Tumor-Derived Heat Shock Protein 96 Mediates In Vitro Activation and In Vivo Expansion of Melanoma- and Colon Carcinoma-Specific T Cells J. Immunol., October 1, 2003; 171(7): 3467 - 3474. [Abstract] [Full Text] [PDF]

				M. Sato, K. Chamoto, and T. Nishimura A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells Int. Immunol., July 1, 2003; 15(7): 837 - 843. [Abstract] [Full Text] [PDF]

				A. Saha, S. K. Chatterjee, K. A. Foon, F. J. Primus, and M. Bhattacharya-Chatterjee Murine Dendritic Cells Pulsed with an Anti-Idiotype Antibody Induce Antigen-specific Protective Antitumor Immunity Cancer Res., June 1, 2003; 63(11): 2844 - 2854. [Abstract] [Full Text] [PDF]

				A. D. Sandler, H. Chihara, G. Kobayashi, X. Zhu, M. A. Miller, D. L. Scott, and A. M. Krieg CpG Oligonucleotides Enhance the Tumor Antigen-specific Immune Response of a Granulocyte Macrophage Colony-stimulating Factor-based Vaccine Strategy in Neuroblastoma Cancer Res., January 15, 2003; 63(2): 394 - 399. [Abstract] [Full Text] [PDF]